-  New data demonstrate dual role of C5 and LTB4 in both bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC). There are no U.S. Food and Drug Administration ( FDA )-approved treatments for either disease. -  Clinical progress across our target conditions Phase II BP data demonstrated a

Biopsy tissue expresses the complement C5a receptor 1 and the leukotriene LTB4 receptor BLT1 on and within the surface of the eye, a previously unreported finding These new findings suggest that inhibition of both LTB4 and C5 by nomacopan may provide therapeutic effect by reducing both

  Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients – No reported drug-related serious adverse events – Achieved marked reduction in Bullous Pemphigoid Disease Area Index (BPDAI) activity score